Mice challenged with E.G7-OVA cells 4 months after one-shot vaccination with HMS-HPS-OVA-PIC show the highest anti-tumor immunity and the highest CD4+, CD8+, and CD86+ cell populations in draining lymph nodes of mice at the endpoint compared with those immunized with HMS-OVA-PIC, HPS-OVA-PIC, and OVA-PIC. The gene discussed is CD8A; the disease is neoplasm.